No full-text available
To read the full-text of this research,
you can request a copy directly from the authors.
Skin manifestations of polycystic ovary syndrome
Abstract
Introduction: The pilosebaceous unit consists of the hair follicle and associated sebaceous and apocrine glands. Hair follicles and sebaceous glands have cellular androgen receptors and react to circulating androgens. Physiological androgen levels induce secondary sexual hair development at puberty, and mild acne is a near universal accompaniment. Androgens also induce pattern hair loss the prevalence and severity increasing with age. Polycystic ovary syndrome (PCOS) is associated with androgen excess and may induce hirsutism and seborrhea and accentuate androgenetic alopecia and acne (Table 8.1). Acanthosis nigricans is a cutaneous marker of insulin resistance that is also associated with PCOS. Physiology of the sebaceous gland: Sebaceous glands occur on all parts of the skin except on the glabrous skin of the palms and soles. They are most numerous on the face, scalp, and back occurring at a concentration of between 400 and 900 glands per square centimeter. Each of the several lobes of the gland has a duct lined with keratinizing squamous epithelium, and these join to form a main duct that enters the follicular canal. Glandular cells, which divide at the periphery, move towards the center of the glands and become increasingly filled with sebaceous material. During this process, cells undergo complete dissolution and discharge all cellular contents into the sebaceous duct. The lipid composition of sebum differs from epidermal lipid in that it contains wax esters and squalene that the former does not, although there are a similar percentage of glycerides (Cunliffe and Simpson 1998).
... Balen et al. (2005) has also reported acne in nearly one third of women with PCOS, and, vice a versa most of women with severe acne are diagnosed with PCOS [12] . The cause of acne in these women is due to androgen stimulated enlargement of the sebaceous glands [13] . In our study vitamin D levels and serum PTH level correlated negatively but the association was not significant (r=-0.041, ...
Correlation of vitamin D and Parathyroid hormone with insulin resistance in PCOS women
Author(s): Saumya Prasad, Pratima Mittal, Rekha Bharti and Jyotsna SuriAbstract: Objectives: To investigate the relation of 25, hydroxyvitamin D concentration and parathyroid hormone with insulin resistance in PCOS women.
Methods: A cross-sectional study was conducted on 50 PCOS (Rotterdam’s criteria) women. Concentrations of 25, hydroxyvitamin D and PTH were measured along with serum levels of fasting sugar and insulin. The homeostasis model assessment index was used as the insulin resistance index.
Results: Total prevalence of vitamin D deficiency (<20ng/ml) was found to be 84% while increased parathyroid hormone level was observed in 64%. There was significant negative correlation between vitamin D deficiency and HOMA-IR (r=-0.67, p<0.01). Positive association was found between increased PTH levels (normal levels: 13.9- 38.3pg/ml) and HOMA-IR.
Conclusion: Vitamin D deficiency and high parathyroid levels are associated with glucose intolerance in PCOS women. Strong correlation between vitamin D deficiency and insulin resistance in PCOS women may suggest that normalization of vitamin D levels may correct insulin resistance.
... Despite being the most common endocrinopathy disorder, believed to affect 6-10% of reproductive-age women, PCOS is the least understood and this may be attributable to the fact that PCOS is difficult to diagnose and symptoms vary in both presence and severity [4,5]. Although incurable, treatment may include lifestyle changes, as well as medication and surgery and whilst these options may help sufferers manage individual symptoms [6], they are often accompanied by a range of side effects [7]. Women with PCOS also have an increased risk of developing other health complications, including type 2 diabetes, cardiovascular disease, stroke and endometrial cancer [8]. ...
Polycystic Ovary Syndrome is a common, chronic condition which affects women living with the condition both physically and psychologically. Social support may be beneficial to sufferers in coping with chronic conditions and the Internet is becoming a common place for accessing social support and information. The aim of this study was to consider the experiences of women living with Polycystic Ovary Syndrome who access and participate in an online support group discussion forum dedicated to issues surrounding this condition.
Fifty participants responded to a series of open-ended questions via an online survey.
Thematic analysis revealed a number of empowering and disempowering experiences associated with online support group participation. The empowering processes reported by members of the group included: Connecting with others who understand; Access to information and advice; Interaction with healthcare professionals; Treatment-related decision making; Improved adjustment and management. In terms disempowering processes, only two were described by group participants: Reading about the negative experiences of others and Feeling like an outsider.
For women living with Polycystic Ovary Syndrome, participation within an online support group may help to empower them in a range of important ways however, there may be some disempowering consequences.
Introduction:
Hirsutism is the presence of excessive body hair in a male pattern distribution in a woman and can affect up to 20% of women. It can be associated with high levels of psychosocial and psychosexual morbidity. It is a common cause for presentation to medical staff particularly endocrinologists, gynaecologists and dermatologists.
Areas covered:
The authors discuss the definition, causes and diagnosis of hirsutism. Current and evolving pharmacotherapy available for hirsutism with an evaluation of the available evidence, consensus opinions and guidelines to date. Physical therapies that can be recommended in combination with medical pharmacotherapies are also outlined.
Expert opinion:
Combined oral contraceptive pills (OCP) are recommended as first line therapy. Addition of oral antiandrogens can be combined for severe cases. Antiandrogens and OCPs have been demonstrated to be the most effective pharmacotherapy available in improving hirsutism. Greater insight is being achieved in the use of antiandrogens and their role in managing hyperandrogenism states such as hirsutism. Insulin sensitisers such as metformin are found to be the least effective. Medical treatments for hirsutism often need to be combined with physical therapies for optimal management. Psychological support should be considered in patients with associated psychosocial morbidity.
Female androgenisation comprises a wide spectrum of heterogeneous dysfunctions and disorders. In order to determine the therapeutic principles of hirsutism and alopecia androgenetica during menopausal transition (MT) and peri-/postmenopause, it is reasonable to confine oneself on a group of androgenised patients among which the skin is pathogenetical in the focus of the referred dysfunction by using our systematically classifying strategy. Such a patient group is classified as "functional cutaneous androgenisation" (FCA). Group FCA is diagnosed via diagnostic level I (screening level) of our classifying algorithm in most cases. Ferriman Gallwey Index and a modified Sinclair Scale are used for grading of hirsutism and alopecia androgenetica, respectively. Dynamic endocrine alterations during MT have to be taken into account regarding hormonal diagnostics. Waxing and laser therapy are frequently used as mechanic and physical therapeutic regimens of hirsutism. Topic treatment of hirsutism is also successfully performed by eflornithine cream, which may additionally support the effect of laser therapy. Minoxidil solution is found to be the first-line therapy for topic treatment of alopecia androgenetica. Steroidal compounds containing the contraceptive combination of ethinylestradiol (EE) and antiandrogen gestagens (AA) are sufficient therapeutic principles in androgenized patients during MT, they are contraindicated in postmenopause. The oral use of spironolactone (S) and/or finasteride, both non-steroidal antiandrogens, is an appropriate systemic therapeutic tool under safe contraceptive control during MT; spironolactone is sufficient for the treatment of alopecia in menopausal women. The use of compounds containing non-contraceptive natural estrogens and AA is indicated for the treatment of FCA only in patients suffering additionally from climacteric and peri-/postmenopausal discomforts. Compounds containing dienogest might be preferred.
Objective: A novel nomenclature as well as a comprehensive, clearly defined classification of functional androgenization (FA) from puberty well into postmenopause have been developed. Data are presented indicating the applicability of this algorithm. Design: Retrospective case-control study involv- ing FA-patients, and controls (C). Methods: FA-patients were classified into five groups, functional cutaneous androgenization (FCA: skin) as well as functional androgenizing syndrome (FAS) I (ovary), II (adrenal), III (multi-organ-disorder with FA, obesity, hyperinsulinaemia) and IV (residual FA dysfunc- tions) using group-specific variable clusters. They are set up by primary (classifying) variables such as cutaneous androgenetic symptoms (acne vulgaris, hirsutism, androgenetic alopecia), body mass index (BMI), testosterone, free androgen index (FAI), polyfollicular ovaries (PFOs), and 1-h-insulin (after oral glucose loading). Groups FCA and FAS I-III were sub-classified through classic full-blown ("a") and non-classic, minimum standard core/miscellaneous clusters ("b"). Variables were allocated as integral part of different clusters (e.g. enhanced BMI: in FCAb, FAS IIb, FAS IIIa/b, and FAS IV). Patients' complete characterization was achieved additionally by using secondary (facultative) variables, e.g. triglycerid levels. Results: The FA-groups included 6, 33, 10, 59, and 18 subjects. All FCA-patients presented cutaneous androgenetic symptoms, PFOs were visualized in all FAS I and III patients. Group FAS Ia showed highest LH levels, and testosterone was higher in FAS I vs. FCA, FAS II, FAS IV and C. Levels of DHEAS were found to be highest in group FAS II. BMI and triglycerids were higher in FAS III vs. FCA, FAS I, FAS II, and C, and one-hr-insulin in FAS III was higher vs. FCA, FAS I, and C. In FAS IV covering the residual FA-patients, several obese, hyperinsulinaemic individuals were classified who showed an increased FAI without the presence of PFOs. Significant P-values were found to be between < 0.05 and < 0.0001. Conclusion: An essential paradigm shift in the diagnosis of androgenized females was presented using an exactly predefined classification of a manageable number of distinguishable FA-entities. An exactly repeatable diagnostic stratification is essential in order to guide customized treatment options by identifying patients' individual dysfunctions and disorders and by improving their risk assessment. Such an approach may also improve the scientific methodology of clinical studies. J Reproduktionsmed Endokrinol 2010; 7 (1): 6-26.
Hirsutism refers to an excess of terminal hair on body sites where terminal hair is normally minimal or absent. Women are more likely to experience stress, anxiety or low self-esteem as a result of hirsutism than men. A number of grading systems are available that define normal and excess body hair; however, they should be interpreted in the context of ethnic and cultural norms. Hirsutism may be idiopathic or secondary to virilization, in which case it may be a sign of a serious medical condition. Androgen activation of hair follicle androgen receptors leads to hair follicle enlargement and increased anagen duration. This in turn produces increased hair diameter and hair fiber elongation. Hirsutism can result from either a high level of tissue androgens or a low activation threshold for the androgen receptor. High tissue androgens can result from elevated levels of circulating androgens (ovarian or adrenal) or local production within skin from chemical precursors. The need for biochemical investigation to identify systemic virilization and any possibly associated medical condition is guided by the severity of the hirsutism, the rate of development and any associated symptoms such as menstrual irregularity, acne, hoarse voice and alopecia. Many pharmaceutical and physical therapies are available to remove excess hair, including shaving, waxing, plucking, depilatory creams, electrolysis, pulsed light and laser therapy. Pharmacotherapy includes topical ornithine decarboxylase inhibition, oral antiandrogens, ovarian and adrenal suppression.
Although androgenic alopecia is recognised to be a symptom of polycystic ovary syndrome (PCOS), it is not known whether polycystic ovaries (PCO) and associated endocrine abnormalities are present in patients who present with alopecia as a primary complaint. We therefore set out to determine the strength of the association between androgenic alopecia and PCO. We examined the prevalence of ultrasound-based polycystic ovarian morphology and associated clinical and biochemical features in a large multiethnic group of women whose presenting complaint was of alopecia, and in a control group.
We studied 89 women of mixed ethnic origin with androgenic alopecia and compared them to 73 control women. A detailed history was taken, anthropometry was performed and assessment of body-hair distribution was made. The presence of PCO was established by pelvic ultrasound scan. Serum gonadotrophins, testosterone, androstenedione, dihydrotestosterone and sex hormone binding globulin concentrations were measured.
Women with alopecia had a higher prevalence of PCO and hirsutism than the control population (PCO: 67% vs 27%, P<0.00001; hirsutism: 21% vs 4%, P=0.003). Women with alopecia (with or without PCO) had higher testosterone, androstenedione and free androgen index than controls, even though few had frankly abnormal androgens.
These findings confirm an association between androgenic alopecia and PCO, and other symptoms of hyperandrogenaemia. Thus most women who present with androgenic alopecia as their primary complaint also have PCO and have indices of abnormal androgen production. Since PCO is a well known risk factor for development of type 2 diabetes, this association has important implications for long-term management.
Fasting and stimulated insulin concentrations in four patients with acanthosis nigricans and polycystic ovary syndrome were compared with four patients, matched for weight and ovarian morphology, without acanthosis. The median fasting serum insulin concentrations were 114.2 and 25.1 mU/l in the respective groups (P = 0.02). One additional patient was investigated before and after an 18% increase in weight which resulted in a 170% increase in fasting insulin concentrations and the development of acanthosis nigricans. These observations suggest that there is variation between individuals in the degree of obesity that results in the development of acanthosis and that obese patients with this skin condition represent the severe end of the spectrum of the polycystic ovary syndrome.
This paper reports an analysis of the clinical, endocrine and ultrasound data within a population of 556 patients with ultrasound-diagnosed polycystic ovaries. Compared with those not so affected, hirsutism was associated with a higher mean serum testosterone concentration, infertility was associated with higher mean gonadotrophin concentrations, obesity was associated with a higher mean serum testosterone concentration, hyperprolactinaemia was associated with a lower mean serum testosterone concentration and smaller ovaries, alopecia was associated with lower mean serum LH and testosterone concentrations, and acanthosis nigricans was associated with obesity and a raised mean serum testosterone concentration. The heterogeneity illustrates the limitations in the use of specific clinical or endocrine criteria as requirements for the diagnosis of the polycystic ovary syndrome.
In the syndrome of familial virilization, insulin resistance, and acanthosis nigricans, the interrelationships are not understood. Twin sisters were studied, along with a lesser affected sister and mother. They manifested amenorrhea, hirsutism, masculinization, hypertension, hyperinsulinemia, hypertriglyceridemia, and hyperprolactinemia. Medical therapy with a gonadotropin-releasing hormone agonist plus an antiandrogen resulted in reversal of the hirsutism, yet with preservation of potential fertility. In response to luteinizing hormone (LH) and follicle-stimulating hormone suppression, there was normalization of the serum androgens, but not of the hyperinsulinemia, hypertriglyceridemia, hyperprolactinemia, hypertension, or acanthosis nigricans. Conclusions: (1) This syndrome may be familial. (2) Medical therapy for the virilization is successful. (3) The hyperandrogenemia is primarily LH dependent and not primarily insulin dependent, although insulin may have an amplification effect. (4) Hyperinsulinemia, hypertriglyceridemia, hyperprolactinemia, and the hypertension are not androgen dependent.
Background
This study examined the relationships of pubertal maturation and sex steroid hormones to the development of acne in young girls. Black (n=317) and white (n=306) premenarchal girls with a mean age of 9.97±0.62 years were evaluated for acne prevalence and severity, pubic hair and areolar maturation, and sex steroid hormone levels.
Results
Overall, 77.8% of the girls had some acne; of the whole group, 48.3% had only comedonal acne, 2.2% had only inflammatory acne, and 27.3% had both types. Although black girls matured at an earlier age than white girls, racial differences in acne were minimal when adjusted for pubertal maturation. Acne increased with advancing maturation; at Tanner pubic hair stages 1, 2, and 3, the prevalence of acne rose from 73.1% to 84.0% and to 90.6%, respectively. Acne lesion counts at seven facial locations revealed a predominance of midfacial acne on the middle aspect of the forehead, nose, and chin. Sex steroid hormone levels measured in 365 of the girls were found to increase significantly during maturation from prepuberty to early puberty. Testosterone-estrogen—binding globulin and the ratio of testosterone to estradiol decreased. In 118 prepubertal girls, estradiol, total and free testosterone, progesterone, testosterone to estradiol ratio, and testosterone-estrogen—bindingglobulin levels were no different whether in subjects with acne or without acne. However, the level of dehydroepiandrosterone sulfate, an androgen of adrenal origin, was significantly higher in prepubertal girls with acne.
Conclusion
Acne, especially the comedonal type, can be the first sign of pubertal maturation in girls, even preceding pubic hair and areolar development. Concentration of dehydroepiandrosterone sulfate is significantly and specifically associated with the initiation of acne in young girls.(Arch Dermatol. 1994;130:308-314)
• Twenty-five women fulfilling the criteria for female alopecia, of either the male pattern baldness type or female pattern baldness type, were evaluated for hormone markers to delineate the clinical baldness patterns. Women with a marked increase in the 3α,17β-androstanediol glucuronide/sex hormone binding globulin ratio and low serum sex hormone binding globulin were noted to have female pattern baldness. This pattern of baldness may represent hair loss from the influence of minimal androgen excess on genetically sensitive hair bulbs in the absence of other signs of maximal androgen excess, including hirsutism, acne, or virilism.
(Arch Dermatol 1986;122:1011-1015)
Objective:
Obese women with polycystic ovary syndrome have a greater frequency of menstrual disturbance and of hirsutism than lean women with the syndrome. Initial studies have demonstrated a marked improvement in endocrine function following a short-term, very low calorie diet. The purpose of this study was to examine the effect of long-term calorie restriction on clinical as well as biochemical abnormalities in obese women with polycystic ovary syndrome.
Design:
We performed a within-group comparison of clinical and biochemical indices before and during dietary treatment.
Patients:
Twenty-four obese women with polycystic ovary syndrome (mean weight 91.5 (SD 14.7) kg) were scheduled for treatment for 6-7 months with a 1000 kcal, low fat diet. Nineteen of the 24 had menstrual disturbances, 12 had infertility and 19 were hirsute.
Measurements and results:
Thirteen subjects lost more than 5% of their starting weight (range 5.9-22%). In this group there was no significant change in gonadotrophin or total serum testosterone levels but there was a marked increase in concentrations of sex hormone-binding globulin (pretreatment: 23.6 (9.5); post-treatment 36.3 (11.8) nmol/l, P = 0.002) and a reciprocal change in free testosterone levels (77 (26) vs 53 (21) pmol/l, P = 0.009). These changes were accompanied by a reduction in fasting serum insulin levels (median (range) 11.2 (5.2-32) vs 2.3 (0.1-13.8) mU/l, P = 0.018) and the insulin response to 75 g oral glucose. There were no significant changes in these indices in the group who lost less than 5% of their initial body weight. Of the 13 women who lost greater than 5% of their pretreatment weight, 11 had menstrual dysfunction. Amongst these women, nine of 11 showed an improvement in reproductive function, i.e. they either conceived (five) or experienced a more regular menstrual pattern. There was a reduction in hirsutism in 40% of the women in this group. By contrast, in the group who lost less than 5% of their initial weight, only one of the eight with menstrual disturbances noted an improvement in reproductive function and none had a significant reduction in hirsutism.
Conclusions:
These data indicate that moderate weight loss during long-term calorie restriction is associated with a marked clinical improvement which reflects the reduction in insulin concentrations and reciprocal changes in SHBG. The improvement in menstrual function and fertility may therefore be consequent upon an increase in insulin sensitivity which, directly or indirectly, affects ovarian function.
Serum testosterone, sex hormone binding globulin (SHBG) and prolactin were measured in thirty-eight women with acne which persisted or started after the age of 18 years. One or more of these levels were abnormal in 76% of patients. Increased testosterone or low SHBG were present alone or in combination in 60% of patients. This group was presumed to have a raised level of non-protein bound, metabolically-available testosterone. Hyperprolactinaemia, which was present in 45% of patients, may be important in view of the reported association with increased adrenal androgens. The hormonal abnormalities may be causally related to the acne and a greater understanding of them may lead to better treatment.
Androgenetic alopecia in the female occurs much more frequently than is generally believed. The condition is still considered infrequent, for it differs, in its clinical picture and in the sequence of events leading to it, from common baldness in men. To facilitate an early diagnosis (desirable in view of the therapeutic possibilities by means of antiandrogens) a classification of the stages of the common form (female type) of androgenetic alopecia in women is presented. The exceptionally observed male type of androgenetic alopecia can be classified according to Hamilton or to the modification of this classification proposed by Ebling & Rook.
The objective was to determine if cyproterone acetate (CPA) therapy for hirsute women demonstrated a dose response.
A double-blind dose-ranging study of the effect of 3 doses of cyproterone acetate for a period of 12 months.
Twenty-one hirsute women received the Dianette contraceptive pill (35 micrograms ethinyl oestradiol + 2 mg CPA, Schering Healthcare, UK), 20 received Dianette plus 20 mg CPA and 19 received Dianette plus 100 mg CPA: supplementary CPA was administered on days 1-10 of the birth control pill cycle as described by Hammerstein.
Hair growth was measured using the clinical scale of Ferriman and Gallwey and by direct measurement of hair shaft diameter and linear growth of hair on the face, forearm, abdomen and thigh.
Thirty-eight women completed 12 months therapy, eight withdrew due to side-effects and 14 were lost to follow-up. All three dose schedules produced significant reductions in clinical hair growth scores. This reduction was seen after 6 months with Dianette alone (P less than 0.005) and after 3 months with both the higher doses (P less than 0.01). There were no significant differences between the effect of different doses at any of the three-monthly time points. Hair diameter measurements were reduced by all doses after 12 months: face by 27*, 37, 37%*, forearm 5, 10, 8%*, abdomen 22*, 39*, 33%*, thigh 12, 24*, 30%* (median reductions (*P less than 0.01) for Dianette, D + 20 mg CPA and D + 100 mg CPA respectively). There were no significant reductions in daily linear growth rates. A comparison of the percentage reduction in hair shaft diameter at each site demonstrated no significant difference between doses, although the reductions by the three doses on the forearm, abdomen and thigh suggested a trend towards a dose response.
We conclude that cyproterone acetate 2 mg daily appears to be as effective as higher doses in the therapy of hirsute women.
To review a group of Australian women presenting to a reproductive endocrinologist with acne and investigate how many had androgen excess and how they had responded to endocrinological therapy.
All patients referred to me over a 12 month period were included in the study and investigated in a standard manner. Medical therapy was given in a non-randomised manner based on clinical and biochemical evidence.
Most patients were referred to my private practice, but all public patients seen over this period were also included.
Subjects were women who presented with acne. Some were also hirsute and/or had menstrual irregularities. The total group consisted of 157 subjects. Patients with thyroid disease, hyperprolactinaemia, and late-onset congenital adrenal hyperplasia, and menopausal women were excluded, and the final study group consisted of 90 subjects.
Women presenting with acne but no hirsutism and an elevated level of dehydroepiandrosterone sulphate were treated with low-dose dexamethasone. All other subjects were treated with ethinyloestradiol and cyproterone acetate.
(i) The diagnosis of polycystic ovary syndrome and (ii) the effect of endocrinological therapy on their acne.
Of the 90 subjects presenting with acne, 67 (74%) were found to have the polycystic ovary syndrome. In all cases the acne was substantially reduced by treatment. All 30 subjects who had previously failed to respond to standard dermatological preparations were successfully treated with combined ethinyloestradiol and cyproterone acetate therapy.
The polycystic ovary syndrome is commonly found amongst women complaining of acne. Some patients will not have excess body hair, obesity or menstrual irregularities. Among women with resistant acne, not responding to conventional treatments, the polycystic ovary syndrome is very common. Treatment with ethinyloestradiol and cyproterone acetate is an extremely effective, safe and well tolerated therapy for these women.
Two hundred and sixty-three women with ultrasound-diagnosed polycystic ovary syndrome were studied of whom 91 (35%) were obese (BMI greater than 25 kg/m2). Obese women with PCOS had a greater prevalence of hirsutism (73% compared with 56%) and menstrual disorders than non-obese subjects. Total testosterone and androstenedione concentrations in serum were similar in the two subgroups but SHBG concentrations were significantly lower, and free testosterone levels higher, in obese compared with lean subjects. In addition, concentrations of androsterone glucuronide, a marker of peripheral 5 alpha-reductase activity, were higher in obese than in non-obese women with PCOS. There were no significant correlations of either SHBG or free testosterone with androsterone glucuronide suggesting that obesity has independent effects on transport and on metabolism of androgen. There were no significant differences between the subgroups in either baseline gonadotrophin concentrations or the pulsatile pattern of LH and FSH secretion studied over an 8-h period. There was, however, an inverse correlation of FSH with BMI, but only in the obese subgroup. In conclusion, the increased frequency of hirsutism in obese compared with lean women with PCOS is associated with increased bio-availability of androgens to peripheral tissues and enhanced activity of 5 alpha-reductase in obese subjects. The mechanism underlying the higher prevalence of anovulation in obese women remains unexplained.
Unlabelled:
In the syndrome of familial virilization, insulin resistance, and acanthosis nigricans, the interrelationships are not understood. Twin sisters were studied, along with a lesser affected sister and mother. They manifested amenorrhea, hirsutism, masculinization, hypertension, hyperinsulinemia, hypertriglyceridemia, and hyperprolactinemia. Medical therapy with a gonadotropin-releasing hormone agonist plus an antiandrogen resulted in reversal of the hirsutism, yet with preservation of potential fertility. In response to luteinizing hormone (LH) and follicle-stimulating hormone suppression, there was normalization of the serum androgens, but not of the hyperinsulinemia, hypertriglyceridemia, hyperprolactinemia, hypertension, or acanthosis nigricans.
Conclusions:
(1) This syndrome may be familial. (2) Medical therapy for the virilization is successful. (3) The hyperandrogenemia is primarily LH dependent and not primarily insulin dependent, although insulin may have an amplification effect. (4) Hyperinsulinemia, hypertriglyceridemia, hyperprolactinemia, and the hypertension are not androgen dependent.
Forty-six women affected by late-onset or persistent acne were studied in order to investigate the frequency of hormonal abnormalities and polycystic ovaries. Hirsutism, perioral distribution of acne lesions and irregular menses were recorded. Hormonal measurements and ovarian echographies were performed. Twenty-four patients were affected with polycystic ovaries, detected by ultrasound scanning. Among the acne patients, the women with ovarian abnormalities had higher values of androstenedione, dehydroepiandrosterone, dehydroepiandrosterone sulfate and luteinizing hormone (LH), and a higher LHT/follicle-stimulating hormone ratio than those with acne and without ovarian abnormalities. This study indicates the prevalence of polycystic ovaries in women with late-onset or persistent acne. Moreover, hormonal abnormalities indicate a subgroup of acne patients defined by the presence of ovarian disorders.
This study evaluates the effect of therapy over a long period of time (36 cycles without interruption) with the monophasic combination containing 0.035 mg of ethinylestradiol and 2 mg of cyproterone acetate (EE35-CPA) on hormonal and clinical parameters of 66 patients with polycystic ovary syndrome (PCOS). During the administration of the pill a significant decrease in the LH/FSH ratio and in adrenal and ovarian androgens has been observed, as well as a significant increase of the Sex Hormone Binding Globulin (SHBG). The progressive decrease of the total androgenic activity explains the clinical results that have been obtained: at the 36th cycle of therapy acne disappeared in 100% of the cases, seborrea in 76.4% and hirsutism in 75%. Our results underline the need for a continuous administration without interruption of the pill with CPA in patients with clinical hyperandrogenic symptoms.
PIP
This study evaluated the effect of therapy over a long period of time (36 cycles without interruption) with the monophasic combination containing 0.035 mg ethinyl estradiol and 2 mg cyproterone acetate (EE35-CPA) on hormonal and clinical parameters of 66 patients with polycystic ovary syndrome. During the administration of the pill, a significant decrease in the LH/FSH ratio and in adrenal and ovarian androgens has been observed, as well as a significant increase in sex hormone binding globulin. The progressive decrease in total androgenic activity explains the clinical results that have been obtained--at the 36th cycle of therapy, acne disappeared in 100% of the cases, seborrhea in 76.4%, and hirsutism in 75%. These results underline the need for continuous administration of the pill with CPA without interruption in patients with clinical hyperandrogenic symptoms.
The effectiveness of the antiandrogen flutamide in combination with an oral contraceptive was studied in 20 patients with moderate to severe hirsutism. Eight patients had no previous therapy, whereas 12 had failed to respond to oral contraceptives, spironolactone, or dexamethasone therapy. Treatment with the antiandrogen flutamide (250 mg twice daily) and an oral contraceptive (Ortho 1/35) resulted in a particularly rapid and marked decrease in the total hirsutism score, which reached the normal range at 7 months. Seborrhea, acne, and hair loss score were also rapidly corrected. Treatment was associated with a decrease in plasma luteinizing hormone, progesterone, and estradiol levels. Plasma sex hormone-binding globulin levels were initially low in 18 to 20 patients but increased significantly during therapy. No clinically significant side effects were observed.
After the description of pelvic ultrasound findings in polycystic ovaries (PCOS) and an assessment of it prevalence in the normal population, the article reports clinical and endocrine features in 300 women with PCOS, and discuses its etiology and the mechanism of anovulation
Plasma dehydroepiandrosterone sulphate, androstenedione, testosterone (T), dihydrotestosterone (DHT), and sex hormone binding globulin (SHBG) have been measured in 64 females and 26 males aged less than 25 years and with acne vulgaris. Oestradiol was measured in the males. Free T and free DHT were calculated. Acne was graded on three sites and the sebum excretion rate (SER) was measured in most patients. With the possible exception of free DHT, none of the plasma steroids or SHBG correlated with acne severity or with SER. Free DHT in the females showed a possible, but weak, correlation with total acne (r = 0.25, P = 0.07), but comparison with male data showed that this was not causative. The role of androgens in acne is permissive and plasma androgen measurements usually have no place in its management.
Prompt evaluation should be carried out for any adolescent complaining of excessive hair growth. The workup should be directed toward the exclusion of androgen secreting neoplasms and correctable adrenal pathology. A minimal workup must include total serum testosterone, DHEA-S, and prolactin. The clinician must then determine if further testing will alter management substantially. Treatment includes removal or neutralization of any discrete source of serum androgens, normalization of altered steroid physiology, and cosmetic correction (electrolysis) of existing hair growth. Successful management will allow normal socialization of the young woman afflicted with this distressing condition.
Tissue resistance to insulin is a major feature underlying the development of acanthosis nigricans in many patients. We report two unusual cases of acanthosis nigricans with contrasting forms of insulin resistance and propose an algorithm for the evaluation of patients with acanthosis nigricans. Further, we present a schematic framework that emphasizes the role of insulin and insulin growth factors in the pathogenesis of acanthosis nigricans.
A group of 22 hirsute women was treated with a combination of 0.030 mg of ethinylestradiol and 0.150 mg of desogestrel (EE-DG) for 6 or 12 months. After 6 months the hair growth was decreased in 17 patients. There was a significant decrease in testosterone/sex hormone binding globulin (T/SHBG) ratio and serum dehydroepiandrosterone sulphate (DHEAS) levels. The changes in the hirsutism and the T/SHBG ratio showed correlation (rho 0.36, P less than 0.05). The patient groups with the best and the poorest clinical response differed in terms of summed changes in the T/SHBG ratio and DHEAS. These findings suggest that the therapeutic effect of the EE-DG is based on combined changes in the related hormone levels.
PIP
A group of 22 hirsute women was treated with a combination of 0.030 mg of ethinylestradiol and 0.150 mg of desogestrel (EE-DG) for 6 or 12 months. After 6 months the hair growth was decreased in 17 patients. In some patients the improvement was, however, not observed until after a period of 6 months. The reduction of the hair growth was slow, especially on the face. There was a significant decrease in testosterone/sex hormone binding globulin (T/SHBG) ratio and serum dehydroepiandrosterone sulphate (DHEAS) levels. The use of contraceptive steroids causes lowering of the plasma ACTH levels. The effect has been thought to account for the reduced DHEAS values in women on oral contraceptives. Many of the patients in the present study had elevated LH and/or suppressed FSH values. The changes in the hirsutism and the T/SHBG ratio showed correlation. The patient groups with the best and the poorest clinical response differed in terms of summed changes in the T/SHBG ratio and DHEAS. These findings suggest that the therapeutic effect of the EE-DG is based on combined changes in the related hormone levels.
Twenty-five women fulfilling the criteria for female alopecia, of either the male pattern baldness type or female pattern baldness type, were evaluated for hormone markers to delineate the clinical baldness patterns. Women with a marked increase in the 3 alpha,17 beta-androstanediol glucuronide/sex hormone binding globulin ratio and low serum sex hormone binding globulin were noted to have female pattern baldness. This pattern of baldness may represent hair loss from the influence of minimal androgen excess on genetically sensitive hair bulbs in the absence of other signs of maximal androgen excess, including hirsutism, acne, or virilism.
Polycystic ovaries were defined with ultrasound imaging in a series of 173 women who presented to a gynaecological endocrine clinic with anovulation or hirsutism. Polycystic ovaries were found in 26% of women with amenorrhoea, 87% with oligomenorrhoea, and 92% with idiopathic hirsutism--that is, hirsutism but with regular menstrual cycles. Fewer than half the anovulatory patients with polycystic ovaries were hirsute, but in 93% of cases there was at least one endocrine abnormality to support the diagnosis of polycystic ovaries--that is, raised serum concentrations of luteinising hormone, raised luteinising hormone: follicle stimulating hormone ratio, or raised serum concentrations of testosterone or androstenedione. This study shows that polycystic ovaries, as defined by pelvic ultrasound, are very common in anovulatory women (57% of cases) and are not necessarily associated with hirsutism or a raised serum luteinising hormone concentration. Most women with hirsutism and regular menses have polycystic ovaries so that the term "idiopathic" hirsutism no longer seems appropriate.
Recession of the frontal and frontoparietal hair line in women has been regarded as a marker for pathologic virilization. In a clinical survey of 564 normal women in the population, frontal and frontoparietal recessions were found in 13% of premenopausal and in 37% of postmenopausal women. Patterned hair loss in women is commoner than hitherto described, particularly after the menopause. In the absence of other signs of virilization, "male-pattern" hair loss would therefore appear to be a poor indicator of gross abnormality of androgen metabolism.
The relationships between the hair growth in different body regions, body mass index (BMI) and age were studied in 225 women of reproductive ages referred for hirsutism. The regularity of the cycles was registered, and 109 of the patients were interviewed for their maximum weight, teenage obesity, and age of menarche. The serum androgens were measured in the follicular phase. The results indicate that facial hirsutism is associated with BMI (rho = 0.41, P less than 0.001) independently of age and the testosterone (T) to sex hormone-binding globulin (SHBG) ratio. Facial hirsutism is also correlated with age (rho = 0.37, P less than 0.001) irrespective of BMI (rho = 0.26, P less than 0.001) or the T/SHBG ratio (rho = 0.43, P less than 0.001). In contrast, the hair growth on trunk area is related to the T/SHBG ratio (rho = 0.35, P less than 0.001) but not to BMI or age when the correlations are adjusted for the grade of hyperandrogenemia. The women with severe facial hirsutism had a higher maximum weight (P less than 0.001) and more teenage obesity (P less than 0.01) than other hirsute patients. They also had a slightly earlier menarche compared with their agemates than the women with mild or absent facial hair (P less than 0.05). The data suggest differences in the regulation of hair growth between the face and trunk areas.
Nine women with acanthosis nigricans and masculinization, who did not appear to have any of the reported syndromes associated with acanthosis nigricans, were studied to characterize the clinical, biochemical, and ovarian morphologic features of their disorders. These patients had the clinical and biochemical profiles of polycystic ovarian disease. All acanthosis nigricans subjects had significant insulin resistance when insulin binding to both circulating monocytes and erythrocytes was compared to the control subjects. Microscopic examination of the ovaries revealed no evidence of recent normal ovulation, sclerosis of the ovarian cortex, follicle cysts, and stromal hyperthecosis. The authors conclude that ovarian stromal hyperthecosis and insulin resistance are consistent findings in the present type of patient. This study provides further evidence supporting a relationship between insulin resistance and human ovarian function.
.— The outermost part of the epidermis, including part of the pilo-sebaceous apparatus, has been sampled, using a cyanoacryalnte adhesive, in patients with acne of varying severity, controls, and in acne patients treated with long term tetracycline. At the site sampled (left upper hack) patients with acne have an increased amount of inspissated material as compared with controls; this appears increased in relation to the severity of the acne. The inspissated material, which is partly keratin and partly lipid, could possibly obstruct the outflow of sebum from the duct.
BDF1 male mice were plucked every 3 weeks for 5 months and samples were taken 4 days alter each plucking. After a single plucking, the epidermal labeling index (LI) was about 5 times the unplucked value. This LI decreased after each plucking and was no different from the unplucked value after the seventh plucking. After each treatment the number of follicles with normal growing hairs was less. However. plucking did not destroy the upper piliary canal or the paired sebaceous glands attached to it.
We measured hormone levels in 59 women and 32 men with longstanding cystic acne resistant to conventional therapy. Affected women had higher serum levels of dehydroepiandrosterone sulfate, testosterone, and luteinizing hormone and lower levels of sex-hormone-binding globulin than controls. Affected men had higher levels of serum dehydroepiandrosterone sulfate and 17-hydroxyprogesterone and lower levels of sex-hormone-binding globulin than controls. To lower dehydroepiandrosterone sulfate, dexamethasone was given to men, and dexamethasone or an oral contraceptive pill, Demulen (or both), was given to women. Of the patients treated for six months, 97 per cent of the women and 81 per cent of the men had resolution or marked improvement in their acne. The dose of dexamethasone required to reduce dehydroepiandrosterone sulfate levels was low, rarely exceeding the equivalent of 20 mg of hydrocortisone per day. We conclude that most patients with therapeutically resistant cystic acne have androgen excess and that lowering elevated dehydroepiandrosterone sulfate results in improvement or remission of acne in most instances.
Elevated serum androgen levels have been reported in patients with acne resistant to conventional dermatologic therapy. This study was designed to investigate the relationship between serum androgen levels and the presence of acne in an unselected population of women seen consecutively by a dermatologist for various dermatologic complaints. Elevated serum testosterone levels were associated with acne regardless of whether this was the presenting complaint or an incidental finding. Women with both acne and hirsutism had higher serum testosterone levels than those with acne alone. Higher incidence of irregular menstrual cycles was noted in women complaining of acne. Normal serum testosterone levels were found only in those patients with regular menstrual cycles and the absence of acne or hirsutism. In conclusion, this study suggests that elevated serum testosterone levels are related to the presence of acne. Attention is called to the possibility that acne may be a clinical manifestation of a disorder with systemic and reproductive consequences.
Serum testosterone, sex hormone binding globulin (SHBG) and prolactin were measured in thirty-eight women with acne which persisted or started after the age of 18 years. One or more of these levels were abnormal in 76% of patients. Increased testosterone or low SHBG were present alone or in combination in 60% of patients. This group was presumed to have a raised level of non-protein bound, metabolically-available testosterone. Hyperprolactinaemia, which was present in 45% of patients, may be important in view of the reported association with increased adrenal androgens. The hormonal abnormalities may be causally related to the acne and a greater understanding of them may lead to better treatment.
We measured plasma sex-hormone binding globulin (SHBG) and testosterone levels in a pilot study of eight women aged 21-41 years who complained of diffuse hair loss; and subsequently in a larger group of fifteen patients of a similar age range. There was a significant reduction in SHBG levels in both groups of patients when compared ot controls, but testosterone values were normal.
To determine the frequency of polycystic ovaries (PCO) on ultrasound and the incidence of clearcut endocrine disorders leading to virilization in patients complaining of hirsutism or androgenic alopecia. The major purpose was to determine a coherent policy for the routine biochemical assessment of such women.
A prospective study of women attending a joint skin/endocrine clinic complaining of these problems.
Three hundred and fifty consecutive women with hirsutism and/or androgenic alopecia were assessed.
Baseline endocrine screens were conducted on two occasions and included measurement of serum testosterone, androstenedione, dehydroepiandrosterone sulphate, sex hormone binding globulin, LH, FSH, 17-hydroxyprogesterone and PRL. The ovaries were visualized by high-resolution pelvic ultrasound scanning.
Eight women were identified with relevant endocrine disorders; of these, one was acromegalic and one had a microprolactinoma--in both cases the association may have been fortuitous. Three had clear-cut 21-hydroxylase deficiency, one a rare hepatic enzyme deficiency (11-reductase), one a virilizing adrenal carcinoma and one a Leydig cell tumour. The latter six cases all had persistently elevated levels of serum testosterone (> 5 nmol/l). In all, 13 women had baseline testosterone levels in excess of 5 nmol/l. Polycystic ovaries were present in 81% of the cases who had erratic cycles and 52% of those with regular cycles; PCO were present in two of the women with 21-hydroxylase deficiency and in the woman with 11-oxoreductase deficiency. The Leydig cell tumour (1.2 cm diameter) was not detected on ultrasound or CT scan.
For the exclusion of enzyme deficiencies and virilizing tumours clinical assessment and a single serum testosterone measurement will suffice.
Women generally regard their hair loss as socially unacceptable and go to great measures to conceal their problem. In some cases, the negative self-image brought about by hair loss may be the basis of psychiatric illness. The purpose of this study was to evaluate a 2% topical minoxidil solution (Rogaine/Regaine, The Upjohn Co, Kalamazoo, Mich) for the treatment of female androgenetic alopecia. A 32-week, double-blind, placebo-controlled trial was conducted in 11 US centers. Three hundred eight women with androgenetic alopecia were enrolled. Two hundred fifty-six of these women completed the trial. A refined photographic technique was used to objectively determine the number of nonvellus hairs regrown.
After 32 weeks of treatment, the number of nonvellus hairs in a 1-cm2 evaluation site was increased by an average of 23 hairs in the 2% minoxidil group and by an average of 11 hairs in the placebo group. The 95% confidence interval for the difference in mean hair count change between the treatment groups was 5.9 to 17.5 hairs. The investigators determined that 13% in the minoxidil-treated group had moderate growth and 50% had minimal growth. This compared with 6% and 33%, respectively, in the placebo-treated group. Similarly, 60% of the patients in the 2% minoxidil group reported that they had new hair growth (20% moderate, 40% minimal) compared with 40% (7% moderate, 33% minimal) of the patients in the placebo group. No evaluations of dense hair growth were reported for either treatment group. No clinically significant changes in vital signs were observed and no serious or unexpected medical events were reported.
Topical minoxidil was significantly more effective than placebo in the treatment of female androgenetic alopecia.
Many doctors frequently encounter hirsute patients. Quantification of hair growth may be useful for diagnosis and follow-up. To establish the reference range for distribution and density of hair in females, and to determine the regions yielding the best discrimination between normal and hirsute women, we studied the distribution and density of terminal hair on 12 body regions assessed on a scale of 0-4. Prospectively, 81 healthy female volunteers and 71 hirsute patients of child-bearing age and Dutch ancestry, who were not receiving medication, and who had not had a recent pregnancy were studied. The reference hair pattern was established for each body region, and the threshold value yielding the highest sensitivity and specificity to evaluate hirsutism was calculated. None of the women in the reference population displayed a score of more than 1 for chin, upper back, upper abdomen and upper arm, or more than 2 for upper lip, side-burns, chest, lower back, lower abdomen, thighs or forearm. The best discrimination between the reference and hirsute populations was obtained with the sum of the scores for four regions: upper lip, chin, lower abdomen and thighs. Independent assessment of hair growth by two investigators revealed excellent agreement. We conclude that a score of more than 1 for chin, upper back, upper abdomen and upper arm, or more than 2 for upper lip, side-burns, chest, lower back, lower abdomen, thighs or forearm is abnormal for Dutch women, and that assessment of hair growth on the upper lip, chin, lower abdomen and thighs is the most suitable way to evaluate hirsutism.
In the May 1993 issue of the Journal we reviewed the basic science of androgen biology in women. We now discuss the evaluation of suspected hyperandrogenism and the therapeutic modalities available.
Disorders of androgen excess in women are common in the practice of dermatology. The literature regarding the evaluation and treatment of women with cutaneous hyperandrogenism (acne, hirsutism, and alopecia) is vast and is contained in numerous subspecialty journals. At first glance, the basic science knowledge required to understand androgen biology appears exceedingly complex. However, an understanding of androgen physiology and a familiarity with the relevant literature are the basis of appropriate evaluations and treatment recommendations. In the first of this two-part series, we review the basic science of androgen biology and pathophysiology in women. The second part of this series will cover the evaluation of suspected hyperandrogenic women and the therapeutic modalities that are available.
The criteria for the diagnosis of the polycystic ovary syndrome (PCOS) have still not been agreed universally. A population of 1741 women with PCOS were studied, all of whom had polycystic ovaries seen by ultrasound scan. The frequency distributions of the serum concentrations of follicle stimulating hormone (FSH), luteinizing hormone (LH), testosterone and prolactin and the body mass index, ovarian volume, uterine cross-sectional area and endometrial thickness were determined and compared with the symptoms and signs of PCOS. Obesity was associated with hirsutism and an elevated serum testosterone concentration and was also correlated with increased rates of infertility and cycle disturbance. The rates of infertility and cycle disturbance also increased with serum LH concentrations > 10 IU/l. A rising serum concentration of testosterone [mean and 95th percentiles 2.6 (1.1-4.8) nmol/l] was associated with an increased risk of hirsutism, infertility and cycle disturbance. The ovarian volume was correlated with serum concentrations of testosterone, LH and the body mass index, which was also correlated with the uterine area. This descriptive data from the largest reported series of women with PCOS enables the development of a management-orientated approach to the syndrome. Women who are overweight can expect an improvement in their symptoms if they lose weight. An elevated concentration of LH (> 10 IU/l) is associated with infertility and treatment should be chosen accordingly. If the serum testosterone concentration is > 4.8 nmol/l, other causes of hyperandrogenism should be excluded.
To determine of the clinical and hormonal effects of finasteride (Proscar; Merck, Sharp, and Dohme, Rahway, NJ) in the treatment of idiopathic hirsutism and hirsutism in patients with polycystic ovary syndrome (PCOS).
Controlled clinical study.
Istitute of Obstetrics and Gynecology, University of Naples "Federico II."
Ten women affected by idiopathic hirsutism and 15 women with PCOS.
Finasteride was administered orally at a daily dose of 5 mg for a period of 6 months.
Rating of hirsutism with the Ferriman-Gallwey method; serum androgen assays.
Finasteride produced a reduction in the average hirsutism scores ( > 50% in all patients), whereas no change was observed in serum T, androstenedione, and DHEAS levels. A significant reduction was measured in serum dihydrotestosterone and 3 alpha, 17 beta-androstenediol glucuronide levels.
This study demonstrates that symptomatic hirsutism has to be considered as a skin disease associated with the increased activity of the 5 alpha-reductase. It also indicates that the selective 5 alpha-reductase inhibitor, finasteride, is very effective and well tolerated in the treatment of both idiopathic hirsutism and of hirsutism in patients with PCOS.
To evaluate the long-term efficacy of the 5 alpha-reductase inhibitor finasteride in idiopathic hirsutism.
Prospective clinical study.
Outpatients in a university hospital.
Fourteen young women with idiopathic hirsutism.
Finasteride, 5 mg once daily, was given for 12 months.
Degree of hirsutism, graded by a modified Ferriman and Gallwey score, serum sex hormones, and serum and urinary markers of 5 alpha-reductase activity. Clinical outcome was evaluated up to and including the 1-year post-treatment period.
The Ferriman and Gallwey score showed a remarkable reduction after 12 months of finasteride treatment (4.4 +/- 0.7 versus 11.8 +/- 1.0; mean +/- SEM). Serum levels of the two 5 alpha-reductase activity markers, dihydrotestosterone and 3 alpha-androstanediol glucuronide, decreased, and urinary C19 and C21 5 beta:5 alpha steroid metabolite ratios consistently increased during finasteride administration. These changes were reversed readily after cessation of treatment. No significant adverse effect was reported. Nine of 14 women completed the 1-year post-treatment follow-up. Their hirsutism scores were increased substantially as compared with values recorded at the end of therapy, but still were lower than baseline values.
The 5 alpha-reductase inhibitor finasteride is effective and well tolerated in longterm treatment of women with idiopathic hirsutism. Post-treatment follow-up suggests that drug effects on hair growth are sustained in the majority of subjects with this disorder.
Forty-four hirsute patients with polycystic ovary syndrome were randomly treated with finasteride (5 mg daily) or flutamide (250 mg twice daily) for 6 consecutive months. Hirsutism was evaluated before and after therapy with the Ferriman-Gallwey score and with measurement of hair diameter (micron). The hairs were taken from four different body areas: the face, abdomen, thighs and forearm. The measurement was carried out with a micrometer applied to the optical microscope. Mean plasma concentrations of luteinizing hormone, follicle-stimulating hormone, 17 alpha-hydroxyprogesterone, androstenedione, testosterone, free testosterone, dehydroepiandrosterone sulfate, insulin, and sex hormone binding globulin were determined before and after therapy. Hematochemical examinations and side-effects were controlled after the treatment. After 6-months' therapy, both antiandrogens significantly reduced the Ferriman-Gallwey score and hair diameter in all the body areas. Finasteride reduced the Ferriman-Gallwey score by 25% and hair diameter by 16-25%; flutamide reduced the score by 20% and hair diameter by 15.3-22%. Abdominal hairs were more sensitive to both drugs. Flutamide induced a significant drop in total testosterone and dehydroepiandrosterone sulfate. No important side-effect or change in the hematochemical parameters was observed. Our data demonstrate that finasteride and flutamide are effective in the treatment of hirsutism in patients with polycystic ovary syndrome.
The methods of hair removal vary between simple inexpensive means of home treatment (shaving, plucking, depilatories) to expensive and potentially time-consuming means used by paraprofessionals, nurses, and/or physicians (electrolysis, lasers, x-ray). The ways in which these different methods induce hair removal, the duration of such removal, and the nuances between devices within the same category of methods are discussed. (J Am Acad Dermatol 1999;40:143-55.) Learning objective: At the completion of this learning activity, participants should be cognizant of the different control mechanisms for hair growth and how the different means of hair removal affect these. Readers will also become familiar with the different types of electrolysis and lasers currently used for hair removal and the advantages and disadvantages of each.
Acanthosis nigricans is a mucocutaneous eruption that occurs in a strikingly exuberant form as a marker for a highly malignant and rapidly fatal internal cancer. Recently, it has been recognized that acanthosis nigricans may also be a relatively common marker for increased long-term risk of the less dramatic but potentially serious systemic disorders associated with insulin resistance and compensatory increased insulin secretion.
Learning objective: At the conclusion of this learning activity participants should be able to discuss ways in which acanthosis nigricans serves as a marker not only for internal malignancy, but also systemic disorders associated with insulin resistance and compensatory increased insulin secretion.
A method was developed for the semiquantitative assessment of body hair growth, and suitable for use in the study of clinical problems associated with hirsuties in women. Five gradings based on densities and areas involved, were determined for each of 11 sites. Findings from application of the method to a control group of 430 women (ages, 15–74 years) are reported. Hair tended to increase on the face and disappear from all other sites with advancing years. In younger age groups a significant amount of hair was found on the forearm and leg in most subjects, but a zero grading was much the commonest finding at all other sites. It is suggested that 2 factors may be involved: one of protective nature with main expression on the forearm and leg, and the other related to hormone levels or sensitivity, with clearest expression elsewhere. An “hormonal” score obtained by adding the gradings obtained from 9 of the 11 sites (excluding the forearm and leg) is being employed in clinical studies.